Nanopharm-logo-with-signature-Pantone (1)
Close this search box.

09 Jul 2024

Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs


Woman in white lab coat and purple gloves pipettes liquid into funnel in sample preparation process for OINDP development.

Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs). Discover the innovative approaches to nasal sprays, and learn about the significant strides being made in transitioning to environmentally friendly, low-global warming potential (GWP) propellants in pressurized metered-dose inhalers (pMDIs). Nanopharm’s commitment to advancing pharmaceutical technologies and delivering client-focused solutions is at the forefront of Rob’s discussion.

Download Interview

Related Posts


Nanopharm Announces Exclusive Collaboration With Fluidda To Accelerate Regulatory Pathway For OINDP Using SmartTrack

Crystal Lake, Illinois, September 22, 2022 – Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE: ATR) in 2019, as part of the company’s strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.

Read More »